Evidence map›Paper›PMID 41987005›Full record

ArticleCancer medicine2026

Identification of lncRNAs Indicating Immune Pathway Activity for Predicting Prognosis and Immunotherapy Response in Pan-Cancer.

Mengyu Xin, Danni He, Yifan Dai, Qian Liu, Rui Sun, Houxing Li, Yujie Zhang, Jiatong Li, Shangwei Ning, Qiuyan Guo and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Mengyu XinCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, China.
Danni HeCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, China.
Yifan DaiCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, China.
Qian LiuCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, China.
Rui SunCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, China.
Houxing LiCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, China.
Yujie ZhangCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, China.
Jiatong LiCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, China.
Shangwei NingCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, China.
Qiuyan GuoDepartment of Gynecology, The First Affiliated Hospital of Harbin Medical University, Harbin, China.
Yue GaoCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, China.ORCID https://orcid.org/0000-0003-0403-6783
Peng WangCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, China.ORCID https://orcid.org/0000-0002-5716-9937

Funding

National Natural Science Foundation of China 82373408National Natural Science Foundation of China 82573333National Natural Science Foundation of China 82573599Natural Science Foundation of Heilongjiang Province YQ2024H013
6 · The paper itself

Abstract

backgroundThe critical role of long non-coding RNAs (lncRNAs) in tumor immunity has garnered increasing attention, and immune pathways are key regulatory factors in tumor immune mechanisms. However, current research on the association between lncRNAs and immune pathways remains limited. Therefore, quantifying this association may provide new insights for predicting prognosis and immunotherapy response.

methodsA method was developed to classify candidate immune-related lncRNAs into complex (CIlncRNAs), moderate (MIlncRNAs), and specific (SIlncRNAs) types based on the breadth of their associations with immune pathway activity. The features of these lncRNA types were then compared from multiple aspects.

resultsThe genomic variations and correlations with DNA methylation of three types of immune-related lncRNAs were significantly different in multiple cancers. CIlncRNAs were more strongly associated with immune infiltration than MIlncRNAs and SIlncRNAs. Lung adenocarcinoma (LUAD) patients were classified into two subtypes based on CIlncRNAs, with one subtype exhibiting better prognosis and higher immune cell infiltration. High expression of CIlncRNAs in immune cells and their role in CD8

conclusionsOverall, our analysis innovatively explores the breadth of associations between lncRNAs and immune pathway activity. We identified CIlncRNAs as potential novel biomarkers for predicting patient prognosis and immunotherapy response, offering valuable insights for clinical practice.

Indexed as

Adenocarcinoma of LungBiomarkers, TumorImmunotherapyLung NeoplasmsNeoplasmsRNA, Long NoncodingDNA MethylationGene Expression Regulation, NeoplasticHumansPrognosisBiomarkers, TumorRNA, Long Noncodingimmune infiltrationimmune‐related pathwaysimmunotherapylong non‐coding RNApan‐cancerprognosis

Identifiers

PMID41987005
PMCPMC13083596

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.